Generic Medication
-
{
- All
- News
- Videos
-
From Pharmacy Of World To Innovation Hub: PM Modi Bats For India's Pharmaceutical Leap
New Delhi, April 14 (IANS) Prime Minister Narendra Modi on Tuesday said that India’s pharma sector is moving up from the pharmacy of the world to a hub of innovation.
-
New Diabetes Generic Drug Gets Approval In US Market: All About Dapagliflozin
Zydus Lifesciences has received USFDA approval for generic dapagliflozin tablets used to treat type 2 diabetes. Here's how the drug works, its benefits, and why it is important for blood sugar control and heart health.
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
Semaglutide Is Not A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It
With generics poised to make semaglutide widely accessible in India, this medication has the potential to transform obesity care. But it cannot replace personalised, long-term treatment plans.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Using Weight-Loss Drugs May Up Your Risk Of Fractures And Gout By 30%, Says New Study
A new study presented at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting suggests that weight-loss drugs may increase the risk of fractures and gout. Here is what you should know about this revelation and how to be careful.
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
From Pharmacy Of World To Innovation Hub: PM Modi Bats For India's Pharmaceutical Leap
New Delhi, April 14 (IANS) Prime Minister Narendra Modi on Tuesday said that India’s pharma sector is moving up from the pharmacy of the world to a hub of innovation.
-
New Diabetes Generic Drug Gets Approval In US Market: All About Dapagliflozin
Zydus Lifesciences has received USFDA approval for generic dapagliflozin tablets used to treat type 2 diabetes. Here's how the drug works, its benefits, and why it is important for blood sugar control and heart health.
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
Semaglutide Is Not A Quick Fix: Bariatric Surgeon Explains The Right Way To Use It
With generics poised to make semaglutide widely accessible in India, this medication has the potential to transform obesity care. But it cannot replace personalised, long-term treatment plans.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Using Weight-Loss Drugs May Up Your Risk Of Fractures And Gout By 30%, Says New Study
A new study presented at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting suggests that weight-loss drugs may increase the risk of fractures and gout. Here is what you should know about this revelation and how to be careful.
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
